1. Twort FW. An investigation on the nature of ultramicroscopic viruses. Bacteriophage 2011;1:127–129.
2. D’Herelle F. On an invisible microbe antagonistic toward dysenteric bacilli: brief note by Mr. F. D’Herelle, presented by Mr. Roux. 1917. Res Microbiol. 2007;158:553–554.
3. Duckworth DH. Who discovered bacteriophage?. Bacteriological reviews, 1976;40.4: 793-802.
4. Summers WC. Bacteriophage research: early history. Bacteriophages: Biology and applications 2005; 5-27.
5. Kutter E, Sulakvelidze A. Bacteriophages: Biology and Applications. Boca Raton, FL: CRC Press; 2005.
6. Salmond GP, Fineran PC. A century of the phage: past, present and future. Nat Rev Microbiol 2015;13(12):777-786.
7. Dublanchet A, Bourne S. The epic of phage therapy. Can J Infect Dis Med Microbiol 2007;18(1):15-18.
8. Sulakvelidze A, Alavidze Z, Morris JrJG. Bacteriophage therapy. Antimicrobial agents and chemotherapy 2001;45(3): 649-659.
9. Pennazıo S. The origin of phage virology. In: Biology Forum/Rivista di Biologia. 2006.
10. Sharp R. Bacteriophages: biology and history. Journal of Chemical Technology & Biotechnology 2001;76(7): 667-672.
11. Deltcheva E, Chylinski K, Sharma CM, et al. CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III. Nature 2011;471:602–607.
12. Dion MB, Oechslin F, Moineau S. Phage diversity, genomics and phylogeny. Nature Reviews Microbiology 2020;18(3): 125-138.
13. Fokine A, Rossmann MG. Molecular architecture of tailed double-stranded DNA phages. Bacteriophage 2014;4(2): e28281.
14. Huang L, Xiang Y. Structures of the tailed bacteriophages that infect Gram-positive bacteria. Current Opinion in Virology 2020;45: 65-74.
15. Lopes A, Tavares P, Petit MA, Guérois R, Zinn-Justin S. Automated classification of tailed bacteriophages according to their neck organization. BMC genomics 2014;15:1-17.
16. Yap ML, Rossmann MG. Structure and function of bacteriophage T4. Future microbiology 2014;9(12): 1319-1327.
17. Leiman PG, Kanamaru S, Mesyanzhinov VV, Arisaka F, Rossmann MG. Structure and morphogenesis of bacteriophage T4. Cellular and Molecular Life Sciences CMLS 2003;60:2356-2370.
18. Xu J, Wang D, Gui M. Structural assembly of the tailed bacteriophage ϕ29. Nat Commun 2019;10:2366.
19. Kropinski A M, Lavigne R. Bacteriophages (Vol. 501). M. R. Clokie (Ed.). Leicester, UK: Humana Press. 2009.
20. Bradley DE. Ultrastructure of bacteriophage and bacteriocins. Bacteriol Rev 1967;31(4):230-314.
21. Ackermann HW. Bacteriophage taxonomy. Microbiology Australia 2011;32(2):90.
22. Ackermann HW, Eisenstark A. The present state of phage taxonomy. Intervirology 1974;3(4):201-219.
23. Ackermann HW. Frequency of morphological phage descriptions in the year 2000. Arch ViroL 2001;146(5):843-857.
24. Turner D, Kropinski, AM, Adriaenssens EM. A roadmap for genome-based phage taxonomy. Viruses, 2021;13(3): 506.
25. Łoś M, Węgrzyn G. Pseudolysogeny. Advances in virus research 2012;82: 339-349.
26. Díaz-Muñoz SL, Koskella B. Bacteria–phage interactions in natural environments. Advances in applied microbiology 2014;89: 135-183.
27. Pfeifer E, Bonnin RA, Rocha EP. Phage-plasmids spread antibiotic resistance genes through infection and lysogenic conversion. MBio 2022;13(5):e01851-22.
28. Olszak T, Latka A, Roszniowski B, Valvano MA, Drulis-Kawa Z. Phage life cycles behind bacterial biodiversity. Current medicinal chemistry 2017;24(36): 3987-4001.
29. Penso G. Cycle of phage development within the bacterial cell. Protoplasma 1955;45,:251-263.
30. Howard-Varona C, Hargreaves KR, Abedon ST, Sullivan MB. Lysogeny in nature: mechanisms, impact and ecology of temperate phages. The ISME journal 2017;11(7):1511-1520.
31. Safa A, Jime JS, Shahel F. Cholera toxin phage: structural and functional diversity between Vibrio cholerae biotypes. AIMS Microbiol 2020;28.6(2):144-151.
32. Fortier LC. The Contribution of Bacteriophages to the Biology and Virulence of Pathogenic Clostridia. Adv Appl Microbiol 2017;101:169-200.
33. Zhang M, Zhang T, Yu M, Chen YL, Jin M. The life cycle transitions of temperate phages: Regulating factors and potential ecological implications. Viruses 2022;14(9): 1904.
34. Ripp S, Miller RV. The role of pseudolysogeny in bacteriophage-host interactions in a natural freshwater environment. Microbiology 1997;143: 2065-2070.
35. Mäntynen S, Laanto E, Oksanen HM, Poranen MM, Díaz-Muñoz SL. Black box of phage–bacterium interactions: Exploring alternative phage infection strategies. Open biology 2021;11(9):
210188.
36. Siringan P, Connerton PL, Cummings NJ, Connerton IF. Alternative bacteriophage life cycles: the carrier state of Campylobacter jejuni. Open biology 2014;4(3): 130200.
37. Zhang Y, Li CX, Zhang XZ. Bacteriophage-mediated modulation of microbiota for diseases treatment. Advanced Drug Delivery Reviews 2021;176: 113856.
38. Duerkop BA. Bacteriophages shift the focus of the mammalian microbiota. PLoS Pathogens 2018;14(10): e1007310.
39. Shkoporov AN, Hill C. Bacteriophages of the human gut: the “known unknown” of the microbiome. Cell host & microbe 2019;25(2): 195-209.
40. Shkoporov AN, Clooney AG, Sutton TD, et al. The human gut virome is highly diverse, stable, and individual specific. Cell host & microbe 2019;26(4): 527-541.
41. Avellaneda-Franco L, Dahlman S, Barr JJ. The gut virome and the relevance of temperate phages in human health. Frontiers in Cellular and Infection Microbiology 2023; 13.
42. Jansen D, Matthijnssens J. The emerging role of the gut virome in health and inflammatory bowel disease: challenges, covariates and a viral imbalance. Viruses 2023;15(1):173.
43. Beller L, Deboutte W, Vieira-Silva S, et al. The virota and its transkingdom interactions in the healthy infant gut. Proceedings of the National Academy of Sciences 2022;119(13): e2114619119.
44. Cadwell K. The virome in host health and disease. Immunity, 2015;42.5: 805-813.
45. Zuo T, Lu XJ, Zhang Y, et al. Gut mucosal virome alterations in ulcerative colitis. Gut, 2019;68(7): 1169-1179.
46. Howe A, Ringus DL, Williams RJ, et al. Divergent responses of viral and bacterial communities in the gut microbiome to dietary disturbances in mice. ISME Journal 2016;10(5):1217–27.
47. Allen HK, Looft T, Bayles DO, et al. Antibiotics in feed induce prophages in swine fecal microbiomes. MBio 2011;2(6): e00260-11.
48. Shkoporov AN, Clooney AG, Sutton TD, et al. The human gut virome is highly diverse, stable, and individual specific. Cell host & microbe 2019;26(4), 527-541.
49. Wright A, Hawkins CH, Anggård EE, Harper DR. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa;
a preliminary report of efficacy. Clin Otolaryngol 2009;34(4):349-57.
50. Rhoads DD, Wolcott RD, Kuskowski MA, et al. Bacteriophage therapy of venous leg ulcers in humans: results of a phase I safety trial. J Wound Care 2009;18:237–8., 240–3.
51. Jault P, Leclerc T, Jennes S, et al. Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled,
double-blind phase 1/2 trial. Lancet Infect Dis 2019;19:35–45.
52. Schooley RT, Biswas B, Gill JJ et al. Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant Acinetobacter baumanni-
iinfection. Antimicrob Agents Chemother 2017;61:e00954–17.
53. Djebara S, Maussen C, De Vos D et al. Processing phage therapy requests in a brussels military hospital: Lessons identified. Viruses 2019;11:265.
54. Dedrick RM, Guerrero-Bustamante CA, Garlena RA, et al. Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus. Nature medi-
cine 2019;25(5):730-733.
55. Little JS, Dedrick RM, Freeman KG, et al. Bacteriophage treatment of disseminated cutaneous Mycobacterium chelonae infection. Nature communications 2022;13(1): 2313.
56. Doub JB, Ng VY, Wilson E, Corsini L, Chan BK. Successful treatment of a recalcitrant Staphylococcus epidermidis prosthetic knee infection with intraoperative bacteriophage therapy. Phar-
maceuticals 2021;14(3):231.
57. Johri AV, Johri P, Hoyle N, Pipia L, Nadareishvili L, Nizharadze D. Case report: chronic bacterial prostatitis treated with phage therapy after multiple failed antibiotic treatments. Frontiers in
Pharmacology 2021;12: 692614